Resverlogix Corp.

News Releases

Sign up for news alerts

2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies
Resverlogix Announces Annual and Special Meeting of Shareholders
Resverlogix To Host Research & Development Update Featuring Key Opinion Leaders in Cardiovascular and Renal Disease
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
Resverlogix Announces Participation in Upcoming Conferences
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
Resverlogix Files 2016 Year-End Disclosure Documents
Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs
Resverlogix Announces Corporate Update Webcast
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016
Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics Symposium
Resverlogix Further Strengthens the Board of Directors and Appoints a New Chairman
Resverlogix Announces Corporate Update Webcast
Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal